# Cameron Wheeler

> Cameron Wheeler is a Series B investor at Deerfield backing Therapeutics. See 17 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Deerfield](https://shizune.co/investors/profile/deerfield)
- Location: New York, United States
- Total investments: 17
- Last investment: Apr 2026
- Lead investor: 65%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/cameron-wheeler-52152b7/

Cameron Wheeler is a Series B investor at Deerfield in New York focused on Therapeutics and Biotechnology. Cameron Wheeler is based out of New York City, New York and is the Partner of Deerfield Management. Cameron previously worked at Eleven Biotherapeutics as a Director of Corporate Development. Cameron attended the Massachusetts Institute of Technology.

## Contacts

5 contacts available for Cameron Wheeler: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/cameron-wheeler?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 6 | 35% |
| Biotechnology | 6 | 35% |
| Health Care | 4 | 24% |
| Life Science | 3 | 18% |
| Biopharma | 2 | 12% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 35% |
| Series A | 5 | 29% |
| Series C | 2 | 12% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Neomorph | Neomorph is building a leading protein degradation entity, focused on “molecular glue” degraders. Its mission is to use this technology to solve critical problems in human health with the discovery and development of innovative new medicines against “undruggable targets.” | $100M | Series B | Apr 13, 2026 |  |
| Perceive Pharma | Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments. | $15M | Series A | Feb 18, 2025 |  |
| Pairwise Plants | Pairwise is a purpose-driven food+tech company dedicated to building a healthier world through better fruits and vegetables. Founded in 2017 by Drs. David Liu, Feng Zhang, J. Keith Joung, Tom Adams, and Haven Baker, Pairwise holds licenses from Harvard and Massachusetts General Hospital to base editing and high-fidelity enzymes, and has anexpanding internal portfolio of tools and traits. The Pairwise team is growing new types of fruits and vegetables, including leafy greens, berries, and stonefruit, with the first products expected within a few years. The Pairwise team is comprised of leaders in agriculture, CPG food, and research and development. | $40M | Series C | Sep 17, 2024 |  |
| Perceive Biotherapeutics | Perceive Biotherapeutics is a biotechnology company pioneering novel technologies and therapeutics in ophthalmology. | $78M | Series B | Jan 05, 2023 |  |
| Perceive Biotherapeutics | Perceive Biotherapeutics is a biotechnology company pioneering novel technologies and therapeutics in ophthalmology. | $78M | Series B | Jan 05, 2023 |  |
| Vicinitas Therapeutics | Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives. Its vision is to use its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit. | $65M | Series A | Jul 28, 2022 |  |
| Ribon Therapeutics | Ribon Therapeutics is a biotechnology company pioneering the discovery of new cancer medicines that target monoPARP proteins, critical regulators of cancer survival mechanisms.The diverse and central functions that PARPs, or poly(ADP-ribose) polymerases, play in cancer cell survival pathways are just emerging, and many of the seminal discoveriesin the field have been made by Ribon’s scientific founders. By combining insights from our founders and an experienced management team, Ribon is building a proprietary drug discovery platform to investigate the molecular action and biological function of a subset of the PARP protein family, called monoPARPs. Based on its platform, Ribon is creating a pipeline of innovative medicines that selectively target monoPARPs to treat cancer and may have the potential to impact other diseases. The company is backed by prominent life science investors, including The Column Group, U.S. Venture Partners, Deerfield Management and Osage University Partners. | $65M | Series C | Jun 14, 2021 |  |
| Ribon Therapeutics | Ribon Therapeutics is a biotechnology company pioneering the discovery of new cancer medicines that target monoPARP proteins, critical regulators of cancer survival mechanisms.The diverse and central functions that PARPs, or poly(ADP-ribose) polymerases, play in cancer cell survival pathways are just emerging, and many of the seminal discoveriesin the field have been made by Ribon’s scientific founders. By combining insights from our founders and an experienced management team, Ribon is building a proprietary drug discovery platform to investigate the molecular action and biological function of a subset of the PARP protein family, called monoPARPs. Based on its platform, Ribon is creating a pipeline of innovative medicines that selectively target monoPARPs to treat cancer and may have the potential to impact other diseases. The company is backed by prominent life science investors, including The Column Group, U.S. Venture Partners, Deerfield Management and Osage University Partners. | $65M | Series C | Jun 14, 2021 |  |
| Nuvalent | Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. It is advancing arobust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. | $135M | Series B | May 11, 2021 |  |
| Nuvalent | Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. It is advancing arobust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. | $135M | Series B | May 11, 2021 |  |

10 of 17 investments shown.

## Co-investors
- [Deerfield](https://shizune.co/investors/profile/deerfield) — VC Fund, 5 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 5 deals together
- [Johnson & Johnson Innovation](https://shizune.co/investors/profile/johnson-johnson-innovation-jjdc) — VC Fund, 5 deals together
- [Deerfield Management](https://shizune.co/investors/profile/deerfield-management-83d0) — VC Fund, 4 deals together
- [Braidwell](https://shizune.co/investors/profile/braidwell) — VC Fund, 3 deals together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 3 deals together

## About Deerfield

VC Fund · New York, United States

Deerfield is an investment management firm. They provide a healthcare ecosystem through information and investment. They also provide private and public investments across the life science, medical device, diagnostic, digital health, and health service industries.

5 contacts available at Deerfield.

| Name | Title | Profile |
| --- | --- | --- |
| Alexander Karnal | Partner and Managing Director | https://shizune.co/investors/profile/alex-karnal |
| Andrew ElBardissi | Partner | — |
| Bryan Sendrowski | Partner | — |
| Cameron Wheeler | Principal | — |
| Elise Wang | Partner, Head of Private Equity Capital Markets | — |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Cameron Wheeler invest in?

Cameron Wheeler invests primarily in Therapeutics, Biotechnology and Health Care startups, most often at Series B and Series A stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Cameron Wheeler?

Public channels for Cameron Wheeler include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Cameron Wheeler last invest?

The most recent investment recorded for Cameron Wheeler closed in Apr 2026. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co